These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia. Casado LF; Hernández JÁ; Jarque I; Echave M; Casado MA; Castro A Eur J Haematol; 2018 Mar; 100(3):264-272. PubMed ID: 29226472 [TBL] [Abstract][Full Text] [Related]
25. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia. Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019 [No Abstract] [Full Text] [Related]
26. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG). Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135 [TBL] [Abstract][Full Text] [Related]
27. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405 [TBL] [Abstract][Full Text] [Related]
28. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Brown JR Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies. Smolewski P; Rydygier D Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971 [TBL] [Abstract][Full Text] [Related]
30. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Sharman JP; Coutre SE; Furman RR; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn IW; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Tausch E; Cramer P; Huang J; Mitra S; Hallek M; O'Brien SM; Stilgenbauer S J Clin Oncol; 2019 Jun; 37(16):1391-1402. PubMed ID: 30995176 [TBL] [Abstract][Full Text] [Related]
31. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392 [TBL] [Abstract][Full Text] [Related]
32. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068 [TBL] [Abstract][Full Text] [Related]
33. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib. Sandova V; Pavlasova GM; Seda V; Cerna KA; Sharma S; Palusova V; Brychtova Y; Pospisilova S; Fernandes SM; Panovska A; Doubek M; Davids MS; Brown JR; Mayer J; Mraz M Haematologica; 2021 Nov; 106(11):2995-2999. PubMed ID: 34196167 [No Abstract] [Full Text] [Related]
34. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936 [TBL] [Abstract][Full Text] [Related]
35. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861 [TBL] [Abstract][Full Text] [Related]
36. Idelalisib Bolsters CLL Regimen. Leslie M Cancer Discov; 2016 Mar; 6(3):OF2. PubMed ID: 26772993 [No Abstract] [Full Text] [Related]